TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.


Roland Kratzer, et al.
AASLD & Hepatology, October 2016 – DOI: 10.1002/hep.28800
Download the poster here
Poster Presentation